HomeCompareBAX vs WAB

BAX vs WAB: Dividend Comparison 2026

BAX yields 2.28% · WAB yields 0.45%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WAB wins by $462.4K in total portfolio value· pulled ahead in Year 3
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
WAB
WAB
● Live price
0.45%
Share price
$237.37
Annual div
$1.06
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$483.0K
Annual income
$337,751.90
Full WAB calculator →

Portfolio growth — BAX vs WAB

📍 WAB pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXWAB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + WAB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
WAB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
WAB
Annual income on $10K today (after 15% tax)
$37.96/yr
After 10yr DRIP, annual income (after tax)
$287,089.12/yr
At 15% tax rate, WAB beats the other by $287,080.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + WAB for your $10,000?

BAX: 50%WAB: 50%
100% WAB50/50100% BAX
Portfolio after 10yr
$251.8K
Annual income
$168,881.08/yr
Blended yield
67.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on WAB right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
WAB
Analyst Ratings
21
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$277.80
+17.0% upside vs current
Range: $221.00 — $315.00
Altman Z
3.3
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
WAB buys
0
No recent congressional trades found for BAX or WAB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXWAB
Forward yield2.28%0.45%
Annual dividend / share$0.36$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%100%
Portfolio after 10y$20.6K$483.0K
Annual income after 10y$10.26$337,751.90
Total dividends collected$602.00$450.4K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$19.75$277.80

Year-by-year: BAX vs WAB ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrWAB PortfolioWAB Income/yrGap
1$10,866$166.33$10,789$89.31+$77.00BAX
2$11,750$123.31$11,725$180.12+$25.00BAX
3← crossover$12,664$90.97$12,911$365.85$247.00WAB
4$13,617$66.89$14,568$753.04$951.00WAB
5$14,619$49.07$17,176$1,588.17$2.6KWAB
6$15,679$35.94$21,878$3,499.96$6.2KWAB
7$16,802$26.30$31,743$8,332.99$14.9KWAB
8$17,998$19.23$56,563$22,598.44$38.6KWAB
9$19,272$14.05$135,791$75,268.61$116.5KWAB
10$20,631$10.26$483,049$337,751.90$462.4KWAB

BAX vs WAB: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

WABStock

Westinghouse Air Brake Technologies Corporation provides technology-based equipment, systems, and services for the freight rail and passenger transit industries worldwide. It operates through two segments, Freight and Transit. The Freight segment manufactures and services components for new and existing freight cars and locomotives; builds new commuter locomotives; rebuilds freight locomotives; supplies railway electronics, positive train control equipment, signal design, and engineering services; and provides related heat exchange and cooling systems. It serves publicly traded railroads; leasing companies; manufacturers of original equipment, including locomotives and freight cars; and utilities. The Transit segment manufactures and services components for new and existing passenger transit vehicles, such as regional trains, high speed trains, subway cars, light-rail vehicles, and buses; refurbishes subway cars; and provides heating, ventilation, and air conditioning equipment, as well as doors for buses and subways. This segment serves public transit authorities and municipalities, leasing companies, and manufacturers of subway cars and buses. It also provides electronically controlled pneumatic braking products; railway electronics; freight car trucks; draft gears, couplers, and slack adjusters; air compressors and dryers; heat exchangers and cooling products; and track and switch products. In addition, the company offers railway braking equipment and related components; friction products; new switcher locomotives; transit locomotive and car overhaul services; and freight locomotive overhaul, modernizations, and refurbishment services. Further, it provides platform screen doors; pantographs; window assemblies; couplers; accessibility lifts and ramps for buses and subway cars; and traction motors. The company was founded in 1869 and is headquartered in Pittsburgh, Pennsylvania.

Full WAB Calculator →
📬

Get this BAX vs WAB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.